Mateon Therapeutics Inc Stock Nasdaq
Equities
US57667K1097
Biotechnology & Medical Research
Sales 2022 | - | Sales 2023 | 0.07 0.1 | Capitalization | 15.27M 20.86M |
---|---|---|---|---|---|
Net income 2022 | 5M 6.83M | Net income 2023 | -7M -9.56M | EV / Sales 2022 | - |
Net Debt 2022 | 11.02M 15.05M | Net Debt 2023 | 12.4M 16.95M | EV / Sales 2023 | 395,316,686 x |
P/E ratio 2022 |
4.5
x | P/E ratio 2023 |
-1.91
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.17% |
Managers | Title | Age | Since |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 19-04-21 |
Director of Finance/CFO | 57 | 19-06-30 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 20-01-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven King
BRD | Director/Board Member | 59 | 20-05-10 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 20-05-10 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 19-04-21 |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |